Medicare beneficiaries will see major pricing shifts as federal negotiations reshape how costly prescription drugs are paid for starting in 2026.

The health sector witnesses significant developments with Eli Lilly's promising weight-loss drug trials and a $40 million ...

Eli Lilly, United Airlines and Urban Outfitters lead five stocks that are showing strength, near buy points, as AI stocks ...

Food-packed tables and endless spirits can present a special challenge for those taking GLP-1 medications like Wegovy, ...

Retatrutide, Eli Lilly’s triple-hormone obesity drug, delivers up to 28.7% weight loss and major knee pain relief in ...

Recent clinical trials of Novo Nordisk’s blockbuster GLP-1 drug semaglutide for Alzheimer’s disease may have failed to show ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Investing.com -- Moody’s Ratings has affirmed Eli Lilly and Company ’s Aa3 senior unsecured notes ratings and long-term issuer rating while revising the outlook to positive from stable, the rating ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

LOS ANGELES, CA / ACCESS Newswire / December 12, 2025 / The landscape of weight management has undergone a seismic shift. Zealthy is one of the fastest-growing telehealth weight-loss platforms in the ...

With foodborne illnesses and changes in Medicare and Medicaid coverage, University of Virginia (UVA) Health experts say never ...

Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from ...